Solid Biosciences (SLDB) Non-Current Deffered Revenue (2017 - 2021)

Solid Biosciences' (SLDB) quarterly Non-Current Deffered Revenue came in at $2.3 million in Q3 2021, down 47.52% quarter-over-quarter from $4.3 million in Q2 2021.

Solid Biosciences (SLDB) Non-Current Deffered Revenue (2017 - 2021) Analysis & Trends

Solid Biosciences has disclosed Non-Current Deffered Revenue across 3 years of filings, most recently posting $2.3 million for Q3 2021.

  • Non-Current Deffered Revenue for Q3 2021 came in at $2.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $2.3 million (changed N/A YoY), and the FY2020 annual result was $10.4 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue came in at $2.3 million for Q3 2021 at Solid Biosciences, down from $4.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $10.4 million in Q4 2020 to a low of $2.3 million in Q3 2021.
  • The 3-year median for Non-Current Deffered Revenue is $4.3 million (2021), against an average of $5.4 million.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 Solid Biosciences 789.54 Mn 408.86 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2021 2.26 Mn
Jun 30, 2021 4.31 Mn
Mar 31, 2021 7.00 Mn
Dec 31, 2020 10.36 Mn
Dec 31, 2017 3.11 Mn